Crossmark

A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy

Crossref DOI link: https://doi.org/10.1007/s40263-019-00607-5

Published Online: 2019-02-19

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gharaylou, Zeinab

Tafakhori, Abbas

Agah, Elmira

Aghamollaii, Vajihe

Kebriaeezadeh, Abbas

Hadjighassem, Mahmoudreza
License Information

Text and Data Mining valid from 2019-02-19
More Information

Article History

First Online: 19 February 2019

Compliance with Ethical Standards

:

: No funding was received for this work.

: Zeinab Gharaylou, Abbas Tafakhori, Elmira Agah, Vajihe Aghamollaii, Abbas Kebriaeezadeh and Mahmoudreza Hadjighassem declare that they have no competing interest.

: The Ethics Committee of Tehran University of Medical Sciences approved this study.

: Informed consent was obtained from all study participants prior to commencement of this study.